Petros Pharmaceuticals, Inc.
PTPI
$0.032
$0.00082.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.72M | 5.11M | 4.02M | 4.12M | 4.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.72M | 5.11M | 4.02M | 4.12M | 4.69M |
| Cost of Revenue | 880.90K | 880.90K | 774.20K | 895.70K | 1.08M |
| Gross Profit | 2.84M | 2.84M | 1.86M | 1.84M | 2.22M |
| SG&A Expenses | 7.50M | 7.54M | 8.97M | 8.67M | 8.63M |
| Depreciation & Amortization | 2.11M | 2.11M | 2.26M | 2.35M | 2.46M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.55M | 11.59M | 13.80M | 13.51M | 14.26M |
| Operating Income | -7.83M | -7.87M | -11.16M | -10.77M | -10.96M |
| Income Before Tax | -13.36M | -11.77M | -2.18M | -4.51M | -6.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.36 | -11.77 | -2.18 | -4.51 | -6.40 |
| Earnings from Discontinued Operations | -1.06M | -2.55M | -2.55M | -2.55M | -2.55M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.42M | -14.32M | -4.73M | -7.06M | -8.94M |
| EBIT | -7.83M | -7.87M | -11.16M | -10.77M | -10.96M |
| EBITDA | -5.00M | -5.04M | -8.18M | -7.71M | -7.78M |
| EPS Basic | -58.66 | -91.47 | -105.16 | -163.08 | -183.89 |
| Normalized Basic EPS | -15.32 | -13.42 | -1.58 | -31.59 | -48.98 |
| EPS Diluted | -58.66 | -91.47 | -105.16 | -163.08 | -183.89 |
| Normalized Diluted EPS | -15.32 | -13.42 | -1.58 | -31.59 | -48.98 |
| Average Basic Shares Outstanding | 2.25M | 1.28M | 974.10K | 665.70K | 454.90K |
| Average Diluted Shares Outstanding | 2.25M | 1.28M | 974.10K | 665.70K | 454.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |